A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors

Study Overview
=================
Brief Summary
-----------------
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and primary efficacy of IBI321 in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable.

Official Title
-----------------
A Phase Ia/Ib, Open-Label, Multi-Center, Study of the Safety, Tolerability and Primary Efficacy of IBI321 in Patients With Advanced Solid Tumors

Conditions
-----------------
Advanced Solid Tumors

Intervention / Treatment
-----------------
* Drug: IBI321


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects able to give voluntary informed consent, understand the study and are willing to follow and complete all the test procedures. Patients with advanced solid tumors who had failed standard treatment. Male or female subjects ≥18 years and ≤75 years. At least one measurable lesion per RECIST version 1.1 Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1 Life expectancy of ≥ 12 weeks. Adequate hematologic and end organ function Exclusion Criteria: Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, targeted therapy, or immunotherapy. Failure to recover from adverse events from the most recent anti-tumor Acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection. Subjects with CNS metastasis unless they are asymptomatic or adequately treated with radiotherapy and/or surgery and subjects are neurologically stable with minimal residual symptoms/signs. Any other serious underlying medical (e.g., uncontrolled hypertension, active uncontrolled infection, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, other serious cardiac conditions not listed in exclusion criteria), psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications. Pregnancy, lactation, breastfeeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Phase Ia Dose-Escalation Stage: IBI321<br> | Drug: IBI321<br>* Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants with Dose-Limiting Toxicities (DLTs) |  | From Day 1 of Cycle 1 to Day 28 | 
| Percentage of Participants with Adverse Events (AEs), treatment-related AE (TRAE), immune-related AEs (irAE) and serious adverse event (SAE) per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 |  | From Day 1 to up to 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Rate (ORR)per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. |  | From Baseline until disease progression (up to 2 years) | 
| Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. |  | From Baseline until disease progression (up to 2 years) | 
| Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. |  | From Baseline until disease progression (up to 2 years) | 
| Overall Survival (OS) |  | From Baseline until disease progression (up to 2 years) | 
| Area Under the Concentration-Time Curve (AUC) of IBI321 |  | From Day 1 up to 2 years | 
| Maximum Serum Concentration (Cmax) of IBI321 |  | From Day 1 up to 2 years | 
| Minimum Serum Concentration (Cmin) of IBI321 |  | From Day 1 up to 2 years | 
| Clearance (CL) of IBI321 |  | From Day 1 up to 2 years | 
| Percentage of Participants with Anti-Drug Antibodies (ADAs) and Neutralizing Antibody (Nab) to IBI321 |  | From Day 1 up to 2 years |